325 related articles for article (PubMed ID: 33986753)
1. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM
Front Immunol; 2021; 12():665541. PubMed ID: 33986753
[TBL] [Abstract][Full Text] [Related]
2. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome].
Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z
Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955
[TBL] [Abstract][Full Text] [Related]
3. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes.
Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE
Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
5. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.
Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF
Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
7. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.
Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ
Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M; Järås M
Front Immunol; 2019; 10():2357. PubMed ID: 31681270
[TBL] [Abstract][Full Text] [Related]
9. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
Arellano-Ballestero H; Sabry M; Lowdell MW
Cells; 2023 Feb; 12(4):. PubMed ID: 36831300
[TBL] [Abstract][Full Text] [Related]
10. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.
Gleason MK; Ross JA; Warlick ED; Lund TC; Verneris MR; Wiernik A; Spellman S; Haagenson MD; Lenvik AJ; Litzow MR; Epling-Burnette PK; Blazar BR; Weiner LM; Weisdorf DJ; Vallera DA; Miller JS
Blood; 2014 May; 123(19):3016-26. PubMed ID: 24652987
[TBL] [Abstract][Full Text] [Related]
11. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia.
Stringaris K; Sekine T; Khoder A; Alsuliman A; Razzaghi B; Sargeant R; Pavlu J; Brisley G; de Lavallade H; Sarvaria A; Marin D; Mielke S; Apperley JF; Shpall EJ; Barrett AJ; Rezvani K
Haematologica; 2014 May; 99(5):836-47. PubMed ID: 24488563
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes.
Liu Z; Guo Y; Huang L; Jia Y; Liu H; Peng F; Duan L; Zhang H; Fu R
Cell Commun Signal; 2022 Oct; 20(1):169. PubMed ID: 36303184
[TBL] [Abstract][Full Text] [Related]
13. Chronic IL-15 Stimulation and Impaired mTOR Signaling and Metabolism in Natural Killer Cells During Acute Myeloid Leukemia.
Bou-Tayeh B; Laletin V; Salem N; Just-Landi S; Fares J; Leblanc R; Balzano M; Kerdiles YM; Bidaut G; Hérault O; Olive D; Aurrand-Lions M; Walzer T; Nunès JA; Fauriat C
Front Immunol; 2021; 12():730970. PubMed ID: 34975835
[TBL] [Abstract][Full Text] [Related]
14. Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance.
Manser AR; Uhrberg M
Cancer Immunol Immunother; 2016 Apr; 65(4):417-26. PubMed ID: 26288343
[TBL] [Abstract][Full Text] [Related]
15. Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.
Aref S; Khaled N; Al Gilany AH; Ayed M; Abouzeid T; Attia D
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2949-2953. PubMed ID: 33112553
[TBL] [Abstract][Full Text] [Related]
16. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome.
Chretien AS; Devillier R; Granjeaud S; Cordier C; Demerle C; Salem N; Wlosik J; Orlanducci F; Gorvel L; Fattori S; Hospital MA; Pakradouni J; Gregori E; Paul M; Rochigneux P; Pagliardini T; Morey M; Fauriat C; Dulphy N; Toubert A; Luche H; Malissen M; Blaise D; Nunès JA; Vey N; Olive D
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34050021
[TBL] [Abstract][Full Text] [Related]
17. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
18. The Activating NKG2C Receptor Is Significantly Reduced in NK Cells after Allogeneic Stem Cell Transplantation in Patients with Severe Graft-versus-Host Disease.
Kordelas L; Steckel NK; Horn PA; Beelen DW; Rebmann V
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27801784
[TBL] [Abstract][Full Text] [Related]
19. Combined flow cytometry natural killer immunophenotyping and KIR/HLA-C genotyping reveal remarkable differences in acute myeloid leukemia patients, but suggest an overall impairment of the natural killer response.
Cianga VA; Rusu C; Pavel-Tanasa M; Dascalescu A; Danaila C; Harnau S; Aanei CM; Cianga P
Front Med (Lausanne); 2023; 10():1148748. PubMed ID: 36960339
[TBL] [Abstract][Full Text] [Related]
20. Increased natural killer cell subsets with inhibitory cytokines and inhibitory surface receptors in patients with recurrent miscarriage and decreased or normal subsets in kidney transplant recipients late post-transplant.
Zhu L; Aly M; Wang H; Karakizlis H; Weimer R; Morath C; Kuon RJ; Toth B; Ekpoom N; Opelz G; Daniel V
Clin Exp Immunol; 2018 Aug; 193(2):241-254. PubMed ID: 29679490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]